FDA Approved: PIOGLITAZONE AND GLIMEPIRIDE — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

The FDA approved a supplemental application for a pioglitazone and glimepiride fixed-dose combination from Prasco Laboratories.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Pioglitazone and Glimepiride (pioglitazone and glimepiride)

Snippet

SUPPL AP for PIOGLITAZONE AND GLIMEPIRIDE (PIOGLITAZONE AND GLIMEPIRIDE)